India to Japan: Ustekinumab Export Trade Route

The India to Japan Ustekinumab corridor is one of India's established pharmaceutical export routes, with 4 shipments documented worth a combined $160.7K USD. The route is dominated by BIOCON BIOLOGICS INDIA LIMITED, which alone accounts for roughly 100% of all export value, reflecting the consolidated nature of India's ustekinumab manufacturing sector.

Across 1 active suppliers, the average shipment value stands at $40.2K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 78% of all shipments, consistent with ustekinumab's non-urgent bulk-order profile.

Shipment activity peaks during July–September, with an average transit time of 29 days port-to-port. The route has recorded an annual growth rate of 26.6%, placing it at rank #10 among India's top ustekinumab export destinations globally.

On the import side, key buyers of Indian ustekinumab in Japan include Shima Hiromi, XXSHIXXO IXX, Naoko Shioji. Shima Hiromi is the single largest importer with 2 shipments valued at $105.7K USD.

India's ustekinumab exports to Japan are driven primarily by a handful of large-scale manufacturers. BIOCON BIOLOGICS INDIA LIMITED with 4 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 1 active exporters signals a competitive but concentrated market — buyers in Japan benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — BIOCON BIOLOGICS INDIA LIMITED — together account for 100% of total trade value on this route. The average shipment value of $40.2K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as ustekinumab bmab 1200 internal and ustekinumab (r-dna origin), suggesting that buyers in Japan tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, Shima Hiromi is the largest importer with 2 shipments worth $105.7K USD — representing 66% of all ustekinumab imports from India on this route.